...
首页> 外文期刊>Journal of Surgical Oncology >Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy
【24h】

Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy

机译:乳腺切除术后淋巴结阴性的早期乳腺癌患者肿瘤复发的临床和病理危险因素

获取原文
获取原文并翻译 | 示例

摘要

Background and Objectives Patients with node-negative breast cancer (NNBC) usually have a good prognosis, but tumor recurrence still compromises survival. In this study, we sought to identify clinical and pathologic factors that predict recurrence. Methods A total of 716 patients who were proved with pT1-2N0M0 breast cancer between 2005 and 2009 were enrolled in this study. Results Forty-seven of the 716 patients developed tumor recurrence during the 47.0 months of median follow-up. The significant risk factors of recurrence were lymphovascular invasion (LVI) (hazard ratio [HR] = 4.60, 95% CI. 2.32-9.10) and Nottingham grade 3 (HR = 4.99, 95% CI. 1.06-23.48); adjuvant radiotherapy (HR = 0.35, 95% CI. 0.14-0.92) prevented tumor recurrence. Furthermore, we investigate the therapeutic impact of adjuvant chemotherapy and radiotherapy on patients with LVI and Nottingham grade 3. The adverse effect of LVI and grade 3 can be abrogated by adjuvant radiotherapy in recurrence-free survival (RFS) (LVI(+)radiotherapy(+), no recurrence; grade 3 (+)radiotherapy(+), HR = 0.82, 95% CI. 0.18-3.70). However, adjuvant chemotherapy did not. Conclusions LVI and Nottingham grade 3 were the independent risk factors predicting tumor recurrence for patients with NNBC. Adjuvant radiotherapy might be considered in NNBC patients with these unfavorable factors to improve the RFS. J. Surg. Oncol. 2013; 108:352-357.
机译:背景与目的淋巴结阴性乳腺癌(NNBC)患者通常预后良好,但肿瘤复发仍会影响生存。在这项研究中,我们试图确定可预测复发的临床和病理因素。方法选取2005年至2009年间共716例经确诊为pT1-2N0M0乳腺癌的患者作为研究对象。结果716例患者中有47例在中位随访47.0个月内出现了肿瘤复发。复发的主要危险因素是淋巴管浸润(LVI)(危险比[HR] = 4.60,95%CI。2.32-9.10)和诺丁汉3级(HR = 4.99,95%CI。1.06-23.48);辅助放疗(HR = 0.35,95%CI。0.14-0.92)可防止肿瘤复发。此外,我们调查了辅助化疗和放疗对LVI和诺丁汉3级患者的治疗效果。辅助放疗可消除LVI和3级对无复发生存期(RFS)的不良影响(LVI(+)放疗( +),无复发; 3(+)放疗(+),HR = 0.82,95%CI。0.18-3.70)。但是,辅助化疗没有。结论LVI和诺丁汉3级是预测NNBC患者肿瘤复发的独立危险因素。具有这些不利因素的NNBC患者可考虑辅助放疗以改善RFS。 J. Surg。 Oncol。 2013; 108:352-357。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号